Display options
Cite
Taylor SJ, Abeywardane A, Liang S, et al. Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS Omega. 2021;6(29):18635-18650doi: 10.1021/acsomega.1c01320.
Taylor, S. J., Abeywardane, A., Liang, S., Xiong, Z., Proudfoot, J. R., Farmer, B. S., Gao, D. A., Heim-Riether, A., Smith-Keenan, L. L., Muegge, I., Yu, Y., Zhang, Q., Souza, D., Panzenbeck, M., Goldberg, D., Hill-Drzewi, M., Margarit, M., Collins, B., Li, J. X., Zuvela-Jelaska, L., Li, J., & Farrow, N. A. (2021). Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS omega, 6(29), 18635-18650. https://doi.org/10.1021/acsomega.1c01320
Taylor, Steven J, et al. "Indole Inhibitors of MMP-13 for Arthritic Disorders." ACS omega vol. 6,29 (2021): 18635-18650. doi: https://doi.org/10.1021/acsomega.1c01320
Taylor SJ, Abeywardane A, Liang S, Xiong Z, Proudfoot JR, Farmer BS, Gao DA, Heim-Riether A, Smith-Keenan LL, Muegge I, Yu Y, Zhang Q, Souza D, Panzenbeck M, Goldberg D, Hill-Drzewi M, Margarit M, Collins B, Li JX, Zuvela-Jelaska L, Li J, Farrow NA. Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS Omega. 2021 Jul 19;6(29):18635-18650. doi: 10.1021/acsomega.1c01320. eCollection 2021 Jul 27. PMID: 34337203; PMCID: PMC8319936.
Copy Download .nbib Format: NLM
Share it on

ACS Omega. 2021 Jul 19;6(29):18635-18650. doi: 10.1021/acsomega.1c01320. eCollection 2021 Jul 27.

Indole Inhibitors of MMP-13 for Arthritic Disorders.

ACS omega

Steven J Taylor, Asitha Abeywardane, Shuang Liang, Zhaoming Xiong, John R Proudfoot, Bennett Sandy Farmer, Donghong A Gao, Alexander Heim-Riether, Lana Louise Smith-Keenan, Ingo Muegge, Yang Yu, Qiang Zhang, Donald Souza, Mark Panzenbeck, Daniel Goldberg, Melissa Hill-Drzewi, Mariana Margarit, Brandon Collins, John Xiang Li, Ljiljana Zuvela-Jelaska, Jun Li, Neil A Farrow

Affiliations

  1. Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, United States.

PMID: 34337203 PMCID: PMC8319936 DOI: 10.1021/acsomega.1c01320

Abstract

Here, we described the design, by fragment merging and multiparameter optimization, of selective MMP-13 inhibitors that display an appropriate balance of potency and physicochemical properties to qualify as tool compounds suitable for

© 2021 The Authors. Published by American Chemical Society.

Conflict of interest statement

The authors declare no competing financial interest.

References

  1. J Clin Invest. 2005 Oct;115(10):2832-42 - PubMed
  2. Drug Discov Today. 2008 Oct;13(19-20):869-74 - PubMed
  3. Vet Pathol. 2015 Sep;52(5):819-26 - PubMed
  4. J Med Chem. 2011 Dec 8;54(23):8174-87 - PubMed
  5. Ann Rheum Dis. 2010 May;69(5):898-902 - PubMed
  6. Chem Biol. 2005 Feb;12(2):181-9 - PubMed
  7. Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81 - PubMed
  8. Lancet. 2010 Sep 25;376(9746):1094-108 - PubMed
  9. Arthritis Res. 2002;4 Suppl 3:S39-49 - PubMed
  10. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5039-43 - PubMed
  11. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):425-38 - PubMed
  12. Development. 2004 Dec;131(23):5883-95 - PubMed
  13. Inflamm Regen. 2020 Sep 7;40:20 - PubMed
  14. Arthritis Res Ther. 2013;15(6):R222 - PubMed
  15. J Med Chem. 2013 Jun 13;56(11):4465-81 - PubMed
  16. Curr Top Med Chem. 2018;18(27):2284-2293 - PubMed
  17. Am J Public Health. 2018 Feb;108(2):256-258 - PubMed
  18. Drug Discov Today. 2020 May;25(5):909-919 - PubMed
  19. Pharmacol Res. 2017 Aug;122:8-19 - PubMed
  20. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5321-4 - PubMed
  21. Med Princ Pract. 2018;27(6):501-507 - PubMed
  22. J Med Chem. 2020 Jun 25;63(12):6423-6435 - PubMed
  23. Drug Discov Today. 2020 Jan;25(1):38-57 - PubMed
  24. J Biol Chem. 2007 Sep 21;282(38):27781-91 - PubMed
  25. Clin Rev Allergy Immunol. 2020 Dec;59(3):334-351 - PubMed
  26. Dis Markers. 2016;2016:4895050 - PubMed
  27. Curr Med Chem. 2019;26(15):2609-2633 - PubMed

Publication Types